Balaxi Pharmaceuticals Limited, a leading IPR branded pharmaceutical company, performed the groundbreaking ceremony of its US-FDA, EU-GMP, WHO - Geneva Compliant Pharmaceutical Formulation Plant at Jadcherla Mandal, Telangana.

The company will be investing Rs. 85 crore in the state-of-the-art facility over a period of one year that will enable them to enter European markets as well as enhance margins in current markets.

To drive this initiative forward, a leading consultant, Spectrum Pharmatech Consultant Private Limited has been appointed for the smooth and time bound project execution. Spectrum Pharmatech Pvt. Ltd., Mumbai is the Design, Engineering, and Turnkey Execution Consultant for this project.

The plant will provide direct and indirect employment to approximately 350+ individuals. This US-FDA, EU-GMP, WHO - Geneva Compliant Pharmaceutical Formulation facility is housed across approximately 1,50,000 square feet, with a capacity of 1 billion tablets per annum, 500 million capsules per annum, and 27 million liquid injections per annum.

The plant’s proposed completion is scheduled for March 2024 and will be abundantly equipped to cater to the demands of global markets. Adhering to global standards for products and services, production from its planned facility will find immediate traction from established demand in existing markets. The robust production will allow backward integration of its supply chain and is expected to start by June 2024.

On the occasion of the groundbreaking ceremony, Ashish Maheshwari, Managing Director, Balaxi Pharmaceuticals Limited said, “For us, the plant commission in Telangana is much more than just a facility, it is a true milestone for Balaxi Pharmaceuticals that will enable us to move from semi regulated to regulated markets. Balaxi will establish a manufacturing ecosystem that affords better control, improves regulatory processes and reduces time to market for new product launches.”

"This facility will also drive backward integration of the supply chain to these countries, currently outsourced through contract manufacturing relationships. It will produce higher efficacy products that enjoy greater acceptance and enhanced profit margins. From the operations standpoint, over the medium term, through this facility, we see several new market opportunities opening up for our product lines,” added Maheshwari.

Swaminathan, MD, Spectrum Pharma Consultants also informed that “The entire timeline and milestones of the project have been meticulously planned and the project will be ready by March 2024.”

Making its mark in the international market, Balaxi Pharma has a unique “Produce, Stock, and Sell Business Model”. The company focuses on frontier markets, with a vast and growing portfolio of 745 product registrations in six countries and 646 new registrations submitted or in the pipeline across multiple therapeutic segments. Presently, the company ranks among fast-growing pharmaceutical companies with a growing presence in countries like Angola, Dominican Republic, Guatemala, El Salvador, and Honduras.